News

BioRx acquires Minn. bleeding-disorder pharmacy

BY Alaric DeArment

CINCINNATI — Specialty pharmacy provider BioRx has acquired another specialty pharmacy provider based in Minnesota, BioRx said Monday.

BioRx, based in Cincinnati and specializing in such bleeding disorders as hemophilia, announced the purchase of Savage, Minn.-based Coagulife, which provides similar services.

"The addition of Coagulife talent and expertise will contribute significantly to our leadership in home hemophilia care," BioRx president and co-founder Phil Rielly said. "We are excited to grow together in delivering outstanding personalized care to the bleeding disorders community."

Jeff Kallberg, who co-founded Coagulife with his brother Daniel in 2004, has hemophilia and speaks around the country about the importance of physical activity for patients with the disorder.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA gives priority review to J&J drug

BY Alaric DeArment

RARITAN, N.J. — The Food and Drug Administration has given priority review to a drug as a treatment for blood-clot disorders, the manufacturer said Monday.

Johnson & Johnson subsidiary Janssen Research & Development said the FDA had given the priority review status to its applications for Xarelto (rivaroxaban) as a treatment for deep-vein thrombosis — a condition in which clots form in one of the large deep veins, usually in the legs — and pulmonary embolism, which occurs when a DVT clot dislodges and is carried to the lung via the heart.

"We are delighted to have received a priority review designation for Xarelto for the treatment of PE and DVT, and also to proven recurrence of these conditions," Janssen R&D VP and cardiovascular franchise medical leader Paul Burton said.

The FDA grants priority review to drugs that offer major advances in care or treat conditions for which there is no adequate therapy. The company announced that it also would withdraw its approval application for Xarelto as a treatment for stent thrombosis in patients with acute coronary syndrome. The drug already is approved for reducing the risk of clots in the legs and lungs of people who have had knee or hip replacement surgery, and to reduce the risk of hemorrhagic and thrombotic strokes and the clots in people with atrial fibrillation not caused by a heart valve problem.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Jel Sert acquires Super C, Pure Kick and Zoic brands

BY Allison Cerra

WEST CHICAGO, Ill. — Jel Sert has acquired three functional beverage brand names from Solis Brands.

The consumer packaged goods food manufacturer said its acquisition of Super C, Pure Kick and Zoic will help the company provide functional beverage options with brands that have been established in the marketplace. Super C is a vitamin and mineral powdered drink mix that delivers functional ingredients, in addition to a healthy boost of vitamin C and antioxidants. Pure Kick is an endurance energy drink mix with a proprietary blend of electrolytes, vitamins and amino acids to enhance performance and energy. Zoic is a ready-to-drink nutrition beverage that provides antioxidants, protein and 26 essential vitamins and minerals.

Jel Sert will immediately take over responsibilities for all sales and distribution of the three brands.

"The addition of the Super C and Pure Kick brands will build on our strong position as a leading branded powdered soft drink manufacturer and allow us to leverage our existing innovation, marketing and distribution capabilities," Jel Sert president Ken Wegner said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?